Ironwood Pharmaceuticals Price To Book vs. Number Of Shares Shorted
| IRWD Stock | USD 3.72 0.26 6.53% |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.74 | 0.9964 |
|
|
For Ironwood Pharmaceuticals profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Ironwood Pharmaceuticals to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Ironwood Pharmaceuticals utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Ironwood Pharmaceuticals's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Ironwood Pharmaceuticals over time as well as its relative position and ranking within its peers.
Ironwood |
Ironwood Pharmaceuticals' Revenue Breakdown by Earning Segment
Check out Risk vs Return Analysis.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ironwood Pharmaceuticals. If investors know Ironwood will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ironwood Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.77) | Earnings Share (0.01) | Revenue Per Share 2.393 | Quarterly Revenue Growth (0.20) | Return On Assets 0.1305 |
The market value of Ironwood Pharmaceuticals is measured differently than its book value, which is the value of Ironwood that is recorded on the company's balance sheet. Investors also form their own opinion of Ironwood Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Ironwood Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ironwood Pharmaceuticals' market value can be influenced by many factors that don't directly affect Ironwood Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ironwood Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Ironwood Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ironwood Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Ironwood Pharmaceuticals Number Of Shares Shorted vs. Price To Book Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Ironwood Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Ironwood Pharmaceuticals value to that of its competitors to determine the firm's financial worth. Ironwood Pharmaceuticals is rated below average in price to book category among its peers. It is rated fourth overall in number of shares shorted category among its peers making about 3,307,893 of Number Of Shares Shorted per Price To Book. Comparative valuation analysis is a catch-all technique that is used if you cannot value Ironwood Pharmaceuticals by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Ironwood Number Of Shares Shorted vs. Price To Book
Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.
Ironwood Pharmaceuticals |
| = | 2.59 X |
Price to Book ratio is mostly used in financial services industries where assets and liabilities are typically represented by dollars. Although low Price to Book ratio generally implies that the firm is undervalued, it is often a good indicator that the company may be in financial or managerial distress and should be investigated more carefully.
Number of Shares Shorted is the total amount of shares that are currently sold short by investors. When a stock is sold short, the short seller assumes the responsibility of repurchasing the stock at a lower price. The speculator will make money if the stock goes down in price or will experience a loss if the stock price goes up.
Ironwood Pharmaceuticals |
| = | 8.57 M |
If a large number of investors decide to short sell an equity instrument within a small period of time, their combined action can significantly affect the price of the stock.
Ironwood Number Of Shares Shorted Comparison
Ironwood Pharmaceuticals is currently under evaluation in number of shares shorted category among its peers.
Ironwood Pharmaceuticals Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Ironwood Pharmaceuticals, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Ironwood Pharmaceuticals will eventually generate negative long term returns. The profitability progress is the general direction of Ironwood Pharmaceuticals' change in net profit over the period of time. It can combine multiple indicators of Ironwood Pharmaceuticals, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | -3 M | -3.2 M | |
| Operating Income | 209 M | 219.5 M | |
| Income Before Tax | -948.1 M | -900.7 M | |
| Total Other Income Expense Net | -1.2 B | -1.1 B | |
| Net Loss | -1 B | -952.1 M | |
| Income Tax Expense | 83.5 M | 87.7 M | |
| Net Loss | -980.9 M | -931.9 M | |
| Non Operating Income Net Other | 8.7 M | 9.2 M | |
| Net Income Applicable To Common Shares | 201.3 M | 211.4 M | |
| Interest Income | 23.2 M | 24.4 M | |
| Net Interest Income | 8.5 M | 8.9 M | |
| Change To Netincome | 82.3 M | 86.5 M | |
| Net Loss | (6.45) | (6.13) | |
| Income Quality | (0.18) | (0.17) | |
| Net Income Per E B T | 1.06 | 0.79 |
Ironwood Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Ironwood Pharmaceuticals. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Ironwood Pharmaceuticals position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Ironwood Pharmaceuticals' important profitability drivers and their relationship over time.
Use Ironwood Pharmaceuticals in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Ironwood Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Ironwood Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Ironwood Pharmaceuticals Pair Trading
Ironwood Pharmaceuticals Pair Trading Analysis
The ability to find closely correlated positions to Ironwood Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Ironwood Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Ironwood Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Ironwood Pharmaceuticals to buy it.
The correlation of Ironwood Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Ironwood Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Ironwood Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Ironwood Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Ironwood Pharmaceuticals position
In addition to having Ironwood Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Corporate Bonds Funds Thematic Idea Now
Corporate Bonds Funds
Funds or Etfs investing in different types of corporate debt instruments. The Corporate Bonds Funds theme has 46 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Corporate Bonds Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Risk vs Return Analysis. For information on how to trade Ironwood Stock refer to our How to Trade Ironwood Stock guide.You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
To fully project Ironwood Pharmaceuticals' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Ironwood Pharmaceuticals at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Ironwood Pharmaceuticals' income statement, its balance sheet, and the statement of cash flows.